Welcome to issue (lucky) #13 of The Ethical Trip! This fortnight:

• Do you know the difference between TAM, SAM and SOM?

• Who thinks they’re in the ‘Cognitive Elite’?

• What to do when someone has a bad trip?

For all this, plus a thoughtfully curated roundup of recent research and unfeasibly niche humour, read on!

Huge thanks to everyone who continues to support my work. Whether it’s feedback, sharing an email, or contributing a few dollars a month via buy me a coffee cactus, it all makes a big difference to me and I’m deeply grateful.

Table of Contents

1. Industry Insights:

   1. Research Round-up

   2. TAM, SAM & SOM for psychedelic investors

2. Philosophical Brief: All Hail The Cognitive Elite

3. Consultancy Corner: Emergency Trip-sitting

4. Reminder - Garden States!

5. A word from Orinoco Visionwolf:

Industry Insights:

Research Round-up

Research isn’t always exciting. (Heck, sometimes it’s not really research.) Here’s some of what I found more interesting from the past two weeks of publications:

Qeadan et al (2025) found that psychedelic use was associated with significantly reduced rates of all adverse substance use disorder outcomes, including all-drug overdose. (I look forward to reading the final version of this paper.)

Mathai et al (2025) reports on the prevalence of self-medication with psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder.

Vercace and Rucker’s (2025) article suggests that while ‘self-integration’ can assist with consolidation and growth form positive psychedelic experiences, it may not protect against severe personality disturbance.

Pelham (2025) finds, perhaps unsurprisingly, that people who microdose self-report positive changes in cognition but also improvements to mood, social lives, and lifestyle.

Lots more below, but only for subscribers!